English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/209460
Share/Impact:
Statistics
logo share SHARE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Deriving Immune Modulating Drugs from Viruses—A New Class of Biologics

AuthorsYaron, Jordan R.; Zhang, Liqiang; Guo, Qiuyun; Burgin, Michelle; Schutz, Lauren N.; Awo, Enkidia; Wise, Lyn; Krause, Kurt L.; Ildefonso, Cristhian J.; Kwiecien, Jacek M.; Juby, Michael; Rahman, Masmudur M.; Chen, Hao; Moyer, Richard W.; Alcami, Antonio; McFadden, Grant; Lucas, Alexandra R.
Issue Date31-Mar-2020
PublisherMultidisciplinary Digital Publishing Institute
CitationJournal of Clinical Medicine 9 (4): 972 (2020)
AbstractViruses are widely used as a platform for the production of therapeutics. Vaccines containing live, dead and components of viruses, gene therapy vectors and oncolytic viruses are key examples of clinically-approved therapeutic uses for viruses. Despite this, the use of virus-derived proteins as natural sources for immune modulators remains in the early stages of development. Viruses have evolved complex, highly effective approaches for immune evasion. Originally developed for protection against host immune responses, viral immune-modulating proteins are extraordinarily potent, often functioning at picomolar concentrations. These complex viral intracellular parasites have “performed the R&D”, developing highly effective immune evasive strategies over millions of years. These proteins provide a new and natural source for immune-modulating therapeutics, similar in many ways to penicillin being developed from mold or streptokinase from bacteria. Virus-derived serine proteinase inhibitors (serpins), chemokine modulating proteins, complement control, inflammasome inhibition, growth factors (e.g., viral vascular endothelial growth factor) and cytokine mimics (e.g., viral interleukin 10) and/or inhibitors (e.g., tumor necrosis factor) have now been identified that target central immunological response pathways. We review here current development of virus-derived immune-modulating biologics with efficacy demonstrated in pre-clinical or clinical studies, focusing on pox and herpesviruses-derived immune-modulating therapeutics.
URIhttp://hdl.handle.net/10261/209460
Identifiersdoi: 10.3390/jcm9040972
Appears in Collections:Colección MDPI
Files in This Item:
File Description SizeFormat 
jcm-09-00972-v2.pdf2,58 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.